Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Oxaliplatin × 90 days × Clear all

Sponsor

Conditions

Colorectal Neoplasms 34 Stomach Neoplasms 27 Rectal Neoplasms 15 Pancreatic Neoplasms 14 Lymphoma, Large B-Cell, Diffuse 14 Colonic Neoplasms 13 Esophageal Neoplasms 12 Adenocarcinoma Of Esophagus 9 Carcinoma, Non-Small-Cell Lung 8 Adenocarcinoma 8 Neoplasms 7 Neoplasm Metastasis 7 Cholangiocarcinoma 7 Ovarian Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Lymphoma 4 Biliary Tract Neoplasms 4 Lung Neoplasms 3 Gallbladder Neoplasms 3 Endometrial Neoplasms 3 Advanced Solid Tumors 3 Triple Negative Breast Neoplasms 2 Pathologic Complete Response 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Locally Advanced Rectal Cancer 2 HER2-positive Gastric Cancer 2 Gastrointestinal Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Colorectal Adenocarcinoma 2

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡